Chicago-New measurement and modeling methods appear to objectively predictureteroscopic performance and skills in a virtual reality environment, accordingto preliminary findings of a study conducted at the University of TexasSouthwestern Medical Center, Dallas.
Dr. Schuster highlights the FDA approval of imaging agent flotufolastat F 18 in prostate cancer
June 22nd 2023"We're excited that the FDA approval of this radiotracer gives us yet more tools at our disposal to diagnose prostate cancer in all its forms, from early to late in the disease process," says David M. Schuster, MD, FACR.